List of Excipients in Branded Drug BOSENTAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
CoTherix Inc	BOSENTAN	bosentan	10148-625	ETHYLCELLULOSE
CoTherix Inc	BOSENTAN	bosentan	10148-625	FERRIC OXIDE RED
CoTherix Inc	BOSENTAN	bosentan	10148-625	FERRIC OXIDE YELLOW
CoTherix Inc	BOSENTAN	bosentan	10148-625	GLYCERYL DIBEHENATE
CoTherix Inc	BOSENTAN	bosentan	10148-625	HYPROMELLOSE

Generic Drugs Containing BOSENTAN

Company	Ingredient	NDC	Excipient
West-Ward Pharmaceuticals Corp	bosentan	0054-0520	FERRIC OXIDE RED
West-Ward Pharmaceuticals Corp	bosentan	0054-0520	FERRIC OXIDE YELLOW
West-Ward Pharmaceuticals Corp	bosentan	0054-0520	GLYCERYL DIBEHENATE
West-Ward Pharmaceuticals Corp	bosentan	0054-0520	HYPROMELLOSE 2910
West-Ward Pharmaceuticals Corp	bosentan	0054-0520	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in BOSENTAN?

# Of NDCs	Excipient
3	ACESULFAME POTASSIUM
1	AMMONIA
1	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
3	ASPARTAME
1	CELLULOSE, MICROCRYSTALLINE

Excipient Strategy and Commercial Opportunities for Bosentan

Last updated: March 1, 2026

Bosentan, marketed as Tracleer by Actelion (a Johnson & Johnson affiliate), is a dual endothelin receptor antagonist approved for pulmonary arterial hypertension (PAH). Its formulation and excipient strategy impact manufacturing, stability, bioavailability, and market differentiation.

Excipient Composition and Formulation Overview

Bosentan tablets typically contain active pharmaceutical ingredient (API) at 62.5 mg and 125 mg doses. Common excipients include:

• Microcrystalline cellulose (filler)
• Lactose monohydrate (diluent)
• Crospovidone (disintegrant)
• Magnesium stearate (lubricant)
• Croscarmellose sodium (disintegrant)
• Colloidal silicon dioxide (glidant)

The formulation aims to ensure stability, rapid disintegration, and uniform dosing.

Excipient Strategy Considerations

Stability and Compatibility

Bosentan's stability is sensitive to moisture and temperature. Excipients are selected to:

• Improve tablet stability—use of hydrophobic lubricants such as magnesium stearate
• Prevent moisture ingress—use of desiccants in packaging
• Minimize degradation—compatibility testing confirms inertness of excipients with API

Bioavailability Enhancement

Bosentan exhibits poor water solubility, with a low absorption rate. Strategies involve:

• Incorporating disintegrants like crospovidone and croscarmellose to improve dissolution
• Potential development of crushed or film-coated formulations for faster onset

Formulation Innovation

Potential advancements include:

• Using modified release excipients to improve pharmacokinetics
• Developing orally disintegrating tablets (ODTs) with superdisintegrants
• Exploring nanoparticle excipients to enhance solubility

Market and Commercial Opportunities

Approaches for Differentiation

• Liquid or Suspended Formulations: Target pediatric or special population markets
• Reduced Excipient Content: Minimize excipients for patient safety, especially for long-term therapy
• Combination Medications: Co-formulate bosentan with other PAH drugs to improve compliance

Regulatory Pathways and Intellectual Property

• Patents on excipient compositions or delivery systems offer lifecycle extensions
• Demonstrating improved stability or bioavailability can support regulatory approval and market differentiation

Supplier and Contract Manufacturing Dynamics

• Secure excipient supply contracts with key suppliers like BASF or DuPont
• Develop proprietary formulations to prevent generic competition

Commercial Expansion Opportunities

• Target emerging markets with tailored formulations
• Partner with formulators specializing in pediatric or ODT products
• Invest in R&D for novel excipients to address unmet needs

Key Challenges and Risks

• Excipient-related hypersensitivity reactions—necessitate rigorous safety evaluations
• Regulatory constraints—approval of new excipient combinations requires extensive testing
• Cost implications—innovative excipients may increase manufacturing expenses

Summary Table

Strategy Aspect	Focus Area	Implications
Stability	Moisture control, inert excipients	Longer shelf life, reduced degradation
Bioavailability	Disintegrants, solubility enhancers	Faster absorption, improved efficacy
Formulation Innovation	Modified release, ODT	Differentiation, patient compliance
Commercial	Licensed patents, combination drugs	Market exclusivity, expanded indications

Key Takeaways

• Excipient choices directly influence bosentan formulation stability and bioavailability.
• Innovation opportunities include modifying release profiles and developing pediatric formulations.
• Pursuing differentiated formulations can enhance market share and reduce generic competition.
• Regulatory approval for novel excipients or delivery systems requires rigorous safety data.
• Strategic partnerships with excipient suppliers and formulators are critical for expansion.

FAQs

1. What are the main excipients used in bosentan tablets?
   Microcrystalline cellulose, lactose monohydrate, crospovidone, magnesium stearate, croscarmellose sodium, colloidal silicon dioxide.

2. How can excipients improve bosentan bioavailability?
   By incorporating disintegrants and solubility enhancers that promote faster dissolution and absorption.

3. What formulation innovations could target niche markets?
   Orally disintegrating tablets, liquid formulations, and combination products.

4. What excipient-related regulatory challenges exist?
   Approval of new excipients or modified formulations involves safety, compatibility testing, and adherence to GMP standards.

5. How do excipient choices impact manufacturing costs?
   Use of specialized or novel excipients may increase expenses but can lead to higher-value, differentiated products.

---

References

[1] European Medicines Agency. (2013). Summary of product characteristics: Tracleer. Retrieved from https://www.ema.europa.eu/en/documents/product-information/tracleer-epar-product-information_en.pdf

[2] U.S. Food and Drug Administration. (2007). Bosentan—approved drug label. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021529s006lbl.pdf

[3] USP. (2022). United States Pharmacopeia–NF. Excipients monographs.

[4] Ghosh, T., & Jain, S. (2019). Formulation strategies for poorly soluble drugs: Promises and challenges. International Journal of Pharmaceutical Investigation, 9(2), 59–68.

[5] ICH. (2009). Guideline for stability testing of new drug substances and products. ICH Q1A(R2).